Company: PTPI
Filing Date: 2025-01-24
Form Type: S-1
Source: 0001410578-25-000047
Chunk: 272

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-01-24
Form: S-1
Chunk 272
---
 accrued and that are unpaid as of January 23, 2025 pursuant to the Certificate of Designations, to February 15, 2025, and (iii) waive any breach or violation of the Purchase Agreement, the Certificate of Designations, or the Warrants resulting from the Company's failure to pay such outstanding amounts. The January 2025 Certificate of Amendment amends the Certificate of Designations to, (i) extend the maturity date to February 15, 2025, (ii) modify the schedule of Installment Dates (as defined in the Certificate of Designations), (iii) amends the restrictive covenant to the Certificate of Designations requiring the Company from January 15, 2025 until February 15, 2025, to maintain unencumbered, unrestricted cash and cash equivalents on hand in amount equal to at least $ 500,000, and (iv) amends the restrictive covenant relating to the change in nature of the Company's business, such that such covenant does not apply to the Company's change in sales strategy related to the Company's Stendra avanafil and product development strategy as it relates to the development and commercialization of a proprietary platform focused on prescription medication to over - the - counter switch solutions. The January 2025 Certificate of Amendment was filed with the Secretary of State of the State of Delaware, effective as of January 24, 2025.

<div align='center'>F-55</div>

#### Up to               Units, Each Unit Consisting of         Shares of Common Stock orPre-Funded Warrants to Purchase          Shares of Common Stock,             Series A Warrants to Purchase          Shares of Common Stock and               Series B Warrants to Purchase          Shares of Common StockUp to        Shares of Common Stock Underlying the Pre-Funded Warrants, Series A Warrants and Series B WarrantsPROSPECTUSDawson James Securities, Inc., 2025​​
#### ​

PART II INFORMATION NOT REQUIRED IN PROSPECTUS

| Item 13. | Other Expenses of Issuance and Distribution |

The following table sets forth the fees and expenses, other than placement agent fees and expenses, payable in connection with the registration of the securities hereunder. All amounts are estimates except the SEC registration fee and the FINRA filing fee.

| Item                             | ​ | Amount     
 to be paid |          | ​ |
|:---------------------------------|:--|:-----------|---------:|:--|
| SEC registration fee             | ​ | $